Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Conditions:   HNSCC;   Lip SCC;   Oral Cavity Cancer;   Oropharynx Cancer;   Larynx Cancer;   Hypopharynx Cancer;   Nasopharynx Cancer;   Sinonasal Carcinoma;   Cutaneous Squamous Cell Carcinoma;   Head and Neck Neoplasms;   Head and Neck Cancer;   Head and Neck Squamous Cell Carcinoma
Intervention:   Drug: Pembrolizumab, Cetuximab
Sponsors:   Assuntina G. Sacco;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified March 2017

http://ift.tt/2nvlatX